Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8293341 | 0.90 | L3MBTL1 (0.60) | POLBSMN1; SMN2MAPTHTTL3MBTL1 | |
| SCHEMBL2892450 | 0.90 | L3MBTL1 (0.60) | POLBSMN1; SMN2MAPTHTTL3MBTL1 | |
| SCHEMBL1538426 | 0.89 | POLB (0.66) | POLBSMN1; SMN2MAPTHTTL3MBTL1 | |
| SCHEMBL7951946 | 0.89 | POLB (0.66) | POLBSMN1; SMN2MAPTHTTL3MBTL1 | |
| SCHEMBL8292876 | 0.88 | POLB (0.58) | POLBSMN1; SMN2MAPTHTTL3MBTL1 | |
| SCHEMBL8084223 | 0.87 | POLB (0.56) | POLBSMN1; SMN2MAPTHTTL3MBTL1 | |
| SCHEMBL14477954 | 0.87 | POLB (0.56) | POLBSMN1; SMN2MAPTHTTL3MBTL1 | |
| SCHEMBL8084202 | 0.87 | POLB (0.56) | POLBSMN1; SMN2MAPTHTTL3MBTL1 | |
| SCHEMBL8076306 | 0.87 | POLB (0.56) | POLBSMN1; SMN2MAPTHTTL3MBTL1 | |
| SCHEMBL15082405 | 0.87 | POLB (0.56) | POLBSMN1; SMN2MAPTHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115151252-B | Iron death inhibitor-diarylamine acetamides | 维泰瑞隆有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| EP-4114375-A1 | FERROPTOSIS INHIBITORS-DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd (KY) | 2023-01-11 | — | — | EP | disclosed |
| CN-115151252-A | Iron death inhibitors diarylamine para-acetamides | 维泰瑞隆有限公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-2734180-B1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES | OREAL (FR) | 2021-03-31 | — | — | EP | disclosed |
| US-10406095-B2 | Compositions and methods for protecting bleached hair and enhanced oxidative hair coloring | GRANT INDUSTRIES, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190083380-A1 | COMPOSITIONS AND METHODS FOR PROTECTING BLEACHED HAIR AND ENHANCED OXIDATIVE HAIR COLORING | GRANT INDUSTRIES, INC. | 2019-03-21 | — | — | US | disclosed |
| US-20140294743-A1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES | L'OREAL (FR) | 2014-10-02 | — | — | US | disclosed |
| US-20140294743-A1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES | L'OREAL (FR) | 2014-10-02 | — | — | US | disclosed |
| US-8585779-B2 | Composition comprising at least one 2-pyrrolidone functionalized in the 4 position with a carboxylic acid or amide, and at least one direct dye or a pigment for dyeing keratin fibres | L'OREAL (FR) | 2013-11-19 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| US-7598250-B2 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598250-B2 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1660447-B1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1701959-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
| WO-2005014540-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190083380-A1 | COMPOSITIONS AND METHODS FOR PROTECTING BLEACHED HAIR AND ENHANCED OXIDATIVE HAIR COLORING | KRT18, CAT, PRKDC | POLB 648/4885SMN1; SMN2 3776/4885MAPT 3865/4885 |
| US-10406095-B2 | Compositions and methods for protecting bleached hair and enhanced oxidative hair coloring | KRT18, CAT, PRKDC | POLB 648/4885SMN1; SMN2 3776/4885MAPT 3865/4885 |
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | POLB 2941/4885SMN1; SMN2 3508/4885MAPT 4829/4885 |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | BACE1, BACE2, PSEN1 | POLB 1261/4885SMN1; SMN2 199/4885MAPT 118/4885 |
| US-20140294743-A1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES | KRT18, LAGE3, TYR | POLB 2028/4885SMN1; SMN2 4825/4885MAPT 611/4885 |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | AIFM2, FECH, GPX4 | POLB 4641/4885SMN1; SMN2 724/4885MAPT 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.